Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART known ✓ | P22102 | 10/20 | 0.76 |
| ▸ | DHFR known ✓ | P00374 | 6/20 | 0.76 |
| ▸ | TYMS known ✓ | P04818 | 5/20 | 0.76 |
| ▸ | FOLR1 | P15328 | 4/20 | 0.76 |
| ▸ | SLC46A1 | Q96NT5 | 4/20 | 0.76 |
| ▸ | ATIC | P31939 | 3/20 | 0.76 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.76 |
| ▸ | SLC19A1 | P41440 | 3/20 | 0.76 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.76 |
| ▸ | FRK | P42685 | 1/20 | 0.76 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL15648731 | 1.00 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL15649748 | 0.99 | GART (0.75) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL17394823 | 0.99 | GART (0.75) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL6034765 | 0.99 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL7969 | 0.99 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL7968 | 0.99 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL2549428 | 0.99 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL3388816 | 0.98 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL124663 | 0.98 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL108860 | 0.98 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10072012-B2 | Process for crystalline pemetrexed dipotassium salt | Shilpa Mecicare Limited (IN) | 2018-09-11 | — | — | US | disclosed |
| EP-3074015-A1 | PROCESS FOR CRYSTALLINE PEMETREXED DIPOTASSIUM SALT | Shilpa Medicare Limited (IN) | 2016-10-05 | — | — | EP | disclosed |
| US-20160280710-A1 | PROCESS FOR CRYSTALLINE PEMETREXED DIPOTASSIUM SALT | SHILPA MEDICARE LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20150259348-A1 | PROCESS FOR PREPARING PEMETREXED DI POTASSIUM AND ITS HYDRATES | SHILPA MEDICARE LIMITED (IN) | 2015-09-17 | — | — | US | disclosed |
| EP-2909208-A1 | PROCESS FOR PREPARING PEMETREXED DI POTASSIUM AND ITS HYDRATES | Shilpa Medicare Limited (IN) | 2015-08-26 | — | — | EP | disclosed |
| WO-2015075601-A1 | PROCESS FOR CRYSTALLINE PEMETREXED DIPOTASSIUM SALT | SHILPA MEDICARE LIMITED (IN) | 2015-05-28 | — | — | WO | disclosed |
| WO-2014060953-A1 | PROCESS FOR PREPARING PEMETREXED DI POTASSIUM AND ITS HYDRATES | SHILPA MEDICARE LIMITED (IN) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060959-A1 | CRYSTALLINE PEMETREXED DIPOTASSIUM PROCESS | SHILPA MEDICARE LIMITED (IN) | 2014-04-24 | — | — | WO | disclosed |
| EP-2213674-B1 | PURIFICATION METHOD OF PEMETREXED SALTS,SODIUM SALTS AND DISODIUM SALTS | CHONGQING PHARM RES INST CO (CN) | 2012-03-07 | — | — | EP | disclosed |
| US-20100305319-A1 | METHOD OF PURIFYING A SALT, SODIUM SALT AND DISODIUM SALT OF PEMETREXED | Chongquing Pharmaceutical Research Institute Co. ltd (CN) | 2010-12-02 | — | — | US | disclosed |
| EP-2213674-A1 | PURIFICATION METHOD OF PEMETREXED SALTS,SODIUM SALTS AND DISODIUM SALTS | Chongqing Pharmaceutical Research Institute Co., Ltd. (CN) | 2010-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280710-A1 | PROCESS FOR CRYSTALLINE PEMETREXED DIPOTASSIUM SALT | DCPS, DPP9, DHX29 | GART 803/4885DHFR 1046/4885TYMS 18/4885 |
| US-20100305319-A1 | METHOD OF PURIFYING A SALT, SODIUM SALT AND DISODIUM SALT OF PEMETREXED | SLC13A3, SLC34A3, SLC28A1 | GART 1306/4885DHFR 117/4885TYMS 71/4885 |
| US-20150259348-A1 | PROCESS FOR PREPARING PEMETREXED DI POTASSIUM AND ITS HYDRATES | DPYD, KCNK5, KCNJ11 | GART 379/4885DHFR 62/4885TYMS 4/4885 |
| US-10072012-B2 | Process for crystalline pemetrexed dipotassium salt | DCPS, DPP9, DHX29 | GART 803/4885DHFR 1046/4885TYMS 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.